IDH1 and cholangiocarcinoma: Pharmacological inhibition of mutant IDH1 offers a greatly needed therapeutic option for patients with IDH1-mutated cholangiocarcinoma, but, as with other targeted therapies, its effectiveness is limited by the development of acquired resistance.